Rohto Pharmaceutical (4527) · InitiativeAdvanced
Addressing the deterioration in the cost ratio caused by product price revisions
First written in FY2023-Q1. 1 of 2 entries say "Advanced", first in FY2027-H1. Latest entry: FY2027-H1.
2entries
5years
0from disclosures
How it moved
Same theme, other companies
Earnings Improvement through Product Price Optimization and Cost ReductionA theme 46 companies write about · 3 as a headwind · 44 as a tailwind
The whole theme swung hardest in 2017: 2 of 12 companies on the "Worse" side.
25 other companies' latest entry also says "Advanced".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 46 companies compared. The sentences above are computed from all 46.Full recordFilings, disclosures and news, newest first
- FY2027-H1AdvancedAnnual report
「In terms of profit, in addition to the effect of higher sales, the cost ratio improved in Japan due to price revisions for Hada Labo and a higher in-house production ratio. As a result, operating profit increased 8.5% to ¥20.953 billion.」
The company described specific measures, including improving the in-house production ratio in addition to revising product prices, that improved the cost ratio, as well as the resulting 8.5% increase in operating profit. - FY2023-Q1First statedAnnual report
「Operating profit increased to ¥135 million, up 26.9% year on year, due to higher operating rates, product price revisions and other factors.」
In response to rising costs for raw materials, supplies and labor, the company identified higher operating rates and product price revisions as countermeasures for the first time.